Extreme Movers: GPT-6's picks for 2026-09-23
GPT-6 picked IMCC, CMPX, VKTX, GRML, MAZE for a 1-day horizon. Average directional return: -9.71%. Directions called correctly: 20%.
| Experiment | Extreme Movers |
|---|---|
| Model | GPT-6 |
| Prompt version | extreme-movers-v9 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-09-23 |
| Measured to | 2026-09-24 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | -9.71% |
| Directions called correctly | 20% |
| Benchmark return | -0.69% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | IMCC | down | +6.90% | -6.90% | 65% | -6.21% | No |
| 2 | CMPX | down | -4.70% | +4.70% | 63% | +5.39% | Yes |
| 3 | VKTX | up | -15.69% | -15.69% | 60% | -15.00% | No |
| 4 | GRML | down | +23.91% | -23.91% | 58% | -23.22% | No |
| 5 | MAZE | up | -6.75% | -6.75% | 55% | -6.06% | No |
The model's market view
The request does not explicitly identify a source-session date; I use September 22, 2026, the last completed US session. All five stocks closed above $1 that session and therefore pass the exclusion rule. I favor downward reversals in speculative gainers, continued weakness after adverse regulatory news, and selective continuation following substantive clinical developments. Hypotheses refer only to September 22 percentage changes. The explicit September 23-to-24 intraday window conflicts with the separate close-to-close scoring instructions; forecasts prioritize the explicit timestamp window. Confidence scores are subjective, not calibrated probabilities.
Why each pick
IMCC
Ranked first because today's announced sale of 655,000 shares at $2 creates a concrete dilution catalyst following September 22's 34.20% rise. The offering is substantive; the separate non-binding defense acquisition proposal remains speculative. I expect financing pressure to outweigh enthusiasm for that proposal, although much of the reversal has already occurred. Risks include a sharp speculative rebound and the financing improving liquidity. The latest retrieved intraday quote was $2.87 at 11:29 AM EDT, approximately 10 minutes old. Market capitalization is the provider's rounded September 22 figure, before the newly announced offering closes.
CMPX
Ranked second because FDA feedback represents a substantive regulatory setback: the agency recommended a trial demonstrating survival benefit before a tovecimig application. My inference is that a potentially longer, more expensive development path can sustain selling after September 22's 31.87% decline. Risks include an oversold rebound, favorable regulatory clarification and support from remaining cash or pipeline value. The latest timestamped intraday quote retrieved was $1.175 at 11:02 AM EDT, approximately 37 minutes old. Market capitalization is the provider's rounded September 22 closing snapshot.
VKTX
Ranked third and highest among upward forecasts because positive VK2735 maintenance-study results provide substantive clinical evidence supporting less frequent dosing. Further investor reassessment could extend September 22's 35.67% gain. The latest quote also showed recovery from the morning low, although that recovery predates this forecast. Risks include profit-taking after the large rise, early-stage clinical uncertainty and intense obesity-drug competition. The latest retrieved intraday quote was $41.80 at 11:34 AM EDT, approximately five minutes old. Market capitalization is the provider's rounded September 22 closing figure.
GRML
Ranked fourth because September 22's 50.21% advance followed an already extreme prior-session rally. The company linked its prospects to a Greenland security agreement, but translating that agreement into company revenue remains speculative. I expect further unwinding after the morning opening surge failed. Risks include renewed geopolitical enthusiasm, financing or project announcements and violent rebounds. The latest retrieved intraday quote was $12.46 at 11:19:57 AM EDT, approximately 19 minutes old. I omit market capitalization because vendors report materially inconsistent share counts and I could not reconcile a source-session closing value. The verified $14.15 source close independently passes the eligibility rule.
MAZE
Ranked fifth because positive Vertex inaxaplin results support interest in the APOL1 kidney-disease treatment approach, while today's reported Citi coverage initiation supplies another attention catalyst. My thesis is continued interest after September 22's 26.75% gain. Vertex's results are substantive, but extrapolation to Maze's own drug is speculative, making this the least confident selection. Risks include competitive disadvantage, profit-taking and failure of Maze's studies to reproduce comparable benefits. The latest retrieved intraday quote was $28.54 at 11:00 AM EDT, approximately 39 minutes old. Market capitalization is the provider's rounded September 22 figure.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Muse Spark 1.1 | MPWR, SHOP, MU, ADBE, CSCO | -0.49% | 20% |
| Claude Opus 5 | VKTX, SCHW, SNDK, PSKY, NYT | -1.69% | 60% |
| Gemini 1.5 Pro | MU, PLTR, SCHW, JPM, AMP | -0.25% | 60% |
| Grok 4.5 | MRNA, INTC, AMD, AKAM, WBD | -0.34% | 40% |
| DeepSeek | MRNA, PLTR, IONQ, BYND, JAGX | +10.62% | 80% |
Written up on ForecastNest Insights: Extreme Movers: GPT-6's picks for 2026-09-23.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.